Evidence map›Paper›PMID 35411783›Full record

ArticleJournal of the American Heart Association2022

Establishing a National Cardiovascular Disease Surveillance System in the United States Using Electronic Health Record Data: Key Strengths and Limitations.

Brent A Williams, Stephen Voyce, Stephen Sidney, Véronique L Roger, Timothy B Plante, Sharon Larson, Michael J LaMonte, Darwin R Labarthe, Bailey M DeBarmore, Alexander R Chang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Geospatial divide in real-world EHR data: Analytical workflow to assess regional biases and potential impact on health equity.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Brent A WilliamsGeisinger Health System Danville PA.ORCID 0000-0002-7721-4483
Stephen VoyceGeisinger Health System Danville PA.
Stephen SidneyKaiser Permanente Northern California Oakland CA.
Véronique L RogerNational Heart, Lung, and Blood Institute Bethesda MD.ORCID 0000-0002-9347-7865
Timothy B PlanteUniversity of Vermont Burlington VT.
Sharon LarsonMain Line Health Wynnewood PA.
Michael J LaMonteState University of New York at Buffalo NY.ORCID 0000-0002-6669-5242
Darwin R LabartheNorthwestern University Chicago IL.
Bailey M DeBarmoreUniversity of North Carolina Chapel Hill NC.ORCID 0000-0002-9911-0917
Alexander R ChangGeisinger Health System Danville PA.
Alanna M ChamberlainMayo Clinic Rochester MN.ORCID 0000-0003-1888-9584
Catherine P BenzigerEssentia Health Duluth MN.ORCID 0000-0002-8992-6197
Geisinger Health System · USEssentia Health · USKaiser Permanente · USMain Line Health · USMayo Clinic · USNational Heart Lung and Blood Institute · USNorthwestern University · USUniversity at Buffalo, State University of New York · USUniversity of North Carolina at Chapel Hill · USUniversity of Vermont · US

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
NCATS NIH HHS UL1 TR001412
6 · The paper itself

Abstract

Cardiovascular disease surveillance involves quantifying the evolving population-level burden of cardiovascular outcomes and risk factors as a data-driven initial step followed by the implementation of interventional strategies designed to alleviate this burden in the target population. Despite widespread acknowledgement of its potential value, a national surveillance system dedicated specifically to cardiovascular disease does not currently exist in the United States. Routinely collected health care data such as from electronic health records (EHRs) are a possible means of achieving national surveillance. Accordingly, this article elaborates on some key strengths and limitations of using EHR data for establishing a national cardiovascular disease surveillance system. Key strengths discussed include the: (1) ubiquity of EHRs and consequent ability to create a more "national" surveillance system, (2) existence of a common data infrastructure underlying the health care enterprise with respect to data domains and the nomenclature by which these data are expressed, (3) longitudinal length and detail that define EHR data when individuals repeatedly patronize a health care organization, and (4) breadth of outcomes capable of being surveilled with EHRs. Key limitations discussed include the: (1) incomplete ascertainment of health information related to health care-seeking behavior and the disconnect of health care data generated at separate health care organizations, (2) suspect data quality resulting from the default information-gathering processes within the clinical enterprise, (3) questionable ability to surveil patients through EHRs in the absence of documented interactions, and (4) the challenge in interpreting temporal trends in health metrics, which can be obscured by changing clinical and administrative processes.

Indexed as

Cardiovascular DiseasesElectronic Health RecordsData CollectionDelivery of Health CareHumansQuality Indicators, Health CareUnited Statescardiovascular diseaseelectronic health recordspopulation surveillance

Identifiers

PMID35411783
PMCPMC9238467
OpenAlexW4223469937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.